A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
- Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1
and Flt3. Phase I study has shown that the toxicity is manageable.
- The purpose of this study is to compare the efficacy and safety profile between
Famitinib and Sunitinib in patients with metastatic renal cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences